Literature DB >> 22212939

Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.

Alshimaa Alaboudy1, Tatsuo Inoue, Kinuyo Hatanaka, Hobyung Chung, Tomoko Hyodo, Seishi Kumano, Takamichi Murakami, Ehab Fawzy Abdou Moustafa, Masatoshi Kudo.   

Abstract

OBJECTIVE: To clarify the diagnostic ability of combining imaging methods to diagnose hepatocellular carcinoma (HCC) using Sonazoid®-enhanced ultrasound (US), gadolinium diethylene-triamine-pentaacetic acid-enhanced (Gd-EOB-DTPA) magnetic resonance imaging (MRI), and contrast-enhanced computed tomography (CECT).
METHODS: A total of 32 patients who underwent surgical resection for HCC were studied. Sonazoid-enhanced US, Gd-EOB-DTPA MRI, CECT, and intraoperative contrast-enhanced ultrasonography were done for all patients. The definitive diagnosis of HCC in those patients was based on histopathological confirmation.
RESULTS: A total of 50 histologically proven HCCs were obtained from 32 patients; their mean (± SD) age was 68.3 years ± 8.1. The mean (± SD) nodule size was 2.6 cm ± 1.9. Twenty percent were well-differentiated HCC, 64% were moderately differentiated HCC, 10% were poorly differentiated HCC, 4% were combined HCC and CCC, and 2% were HCC with severe necrosis. The overall diagnostic sensitivity of CEUS, CECT, and Gd-EOB-DTPA MRI was 72, 74, and 86%, respectively; however, there was no significant difference between the three imaging modalities in diagnosing typical HCC (p = 0.092). When combining the diagnostic ability of the different imaging modalities, the diagnostic sensitivity of Sonazoid-enhanced US and Gd-EOB-DTPA MRI was 90%, while addition of Sonazoid-enhanced US to CECT and CECT to Gd-EOB-DTPA MRI had a sensitivity of 82 and 88%, respectively. There was no significant difference between the three imaging combinations (p = 0.970).
CONCLUSION: Sonazoid-enhanced US and Gd-EOB-DTPA MRI can be confidently used in daily clinical practice for the management of HCC.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212939     DOI: 10.1159/000333264

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  18 in total

1.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

2.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

4.  Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment.

Authors:  Xiao-Yun Zhang; Yan Luo; Tian-Fu Wen; Li Jiang; Chuan Li; Xiao-Fei Zhong; Jing-Yi Zhang; Wen-Wu Ling; Lu-Nan Yan; Yong Zeng; Hong Wu
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 5.  Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.

Authors:  Ying Zhang; Kazushi Numata; Yuewu Du; Shin Maeda
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 6.  Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Vanja Giljaca; Agostino Colli; Mirella Fraquelli; Giovanni Casazza; Damir Miletic; Davor Štimac
Journal:  Cochrane Database Syst Rev       Date:  2021-10-06

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

Review 8.  Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.

Authors:  Hitoshi Maruyama; Tadashi Sekimoto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2015-12-22       Impact factor: 6.772

9.  HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.

Authors:  A M Attallah; M M Omran; A A Attallah; S O Abdallah; K Farid; H Darwish; I El-Dosoky; Y M Shaker
Journal:  Br J Cancer       Date:  2013-08-27       Impact factor: 7.640

10.  Potential value of sonazoid-enhanced intraoperative laparoscopic ultrasonography for liver assessment during laparoscopy-assisted colectomy.

Authors:  Tetsuya Itabashi; Akira Sasaki; Koki Otsuka; Toshimoto Kimura; Hiroyuki Nitta; Go Wakabayashi
Journal:  Surg Today       Date:  2013-05-14       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.